The present study describes the effect of culture medium components on progesterone release from human granulosa-luteal cells isolated from patients undergoing in-vitro fertilization (IVF). Progesterone release was selectively measured as a central parameter of in-vitro luteinization, a process believed to decrease the success rate of IVF treatments. Ten different media of relevance to embryo culture were investigated for their effect on progesterone release in unstimulated granulosa cell cultures and in cultures stimulated with human chorionic gonadotrophin (HCG) (1 IU/ml) during 4 days in vitro. Culture media supplemented with human serum yielded the greatest secretion of progesterone. Supplementation with fetal calf serum caused an intermediate pattern of progesterone release. Substitution of serum with a synthetic replacement (Medi-CultR SSR 1 and 2), lacking hormones, cholesterol and growth factors, led to a minimal output of progesterone from granulosa-luteal cells. Complex media (RPMI 1640 and Ham's F10) generally caused a greater progesterone release than simple salt solution (EBSS). No effect of insulin was detected when added to serum-free media.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/oxfordjournals.humrep.a137266 | DOI Listing |
Anim Reprod
January 2025
Department of Comparative Biosciences, College of Veterinary Medicine, University of Illinois at Urbana-Champaign, Urbana, IL, USA.
This study aimed to develop a non-surgical method to neutralize reproduction in female dogs. Female Beagle puppies, aged 6 days, were treated with pellets designed to release estradiol benzoate (EB; 1.0 mg) and progesterone (P4; 5.
View Article and Find Full Text PDFMedicine (Baltimore)
January 2025
Department of Internal Medicine, Division of Hematology and Oncology, Jeonbuk National University Hospital, Jeonbuk National University Medical School, Jeonju, Republic of Korea.
Rationale: Aggressive angiomyxoma (AAM) is an exceptionally rare mesenchymal tumor that predominantly manifests in the female genital organs during the reproductive age. Its rarity alone makes it a fascinating subject for study. The diagnosis of AAM necessitates differentiation from other benign or mesenchymal tumors and can be confirmed through immunohistochemistry (IHC) staining.
View Article and Find Full Text PDFJBRA Assist Reprod
January 2025
Racine IVF Unit, Fertility Institute, Lis Maternity Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel affiliated to the Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Objective: To compare recombinant FSH (rFSH) with highly purified-human menopausal gonadotrophin (hp-hMG) on ovarian response in women undergoing elective fertility preservation (FP).
Methods: This retrospective study included 456 women who underwent elective FP with gonadotropin-releasing hormone (GnRH) antagonist or progestin-primed ovarian stimulation (PPOS) protocols between 01/2017-12/2021. Only the first treatment cycle of each woman was included.
Anim Reprod Sci
January 2025
University of Georgia, Department of Animal and Dairy Sciences, Athens, GA 30602, USA. Electronic address:
This study evaluated the impact of luteal blood perfusion (BP) and expression of estrus on pregnancy rates of Bos taurus embryo recipients exposed to fixed-timed embryo transfer (FTET) using a gonadotropin-releasing hormone (GnRH)- and progesterone-based ovulation synchronization protocol. Postpartum beef cows (n = 746) were exposed to a GnRH/progesterone-based ovulation synchronization protocol. Luteal morphometry and BP were assessed using color Doppler ultrasonography 9 days after CIDR removal concurrently with FTET.
View Article and Find Full Text PDFCurr Opin Obstet Gynecol
December 2024
Mount Sinai Medical Center, Miami Beach, Florida, USA.
Purpose Of Review: Endometrial cancer (EC) is rising in incidence, particularly in younger, premenopausal women, due to increasing rates of obesity and delayed childbearing. This review evaluates current and emerging endocrine therapies, with a focus on fertility-preserving approaches for early-stage EC and treatment options for advanced or recurrent disease.
Recent Findings: Fertility-sparing endocrine therapies, such as medroxyprogesterone acetate, megestrol acetate, and levonorgestrel-releasing intrauterine devices, achieve high response rates but carry recurrence risks.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!